News | May 13, 2023
Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
Launches Thalassemia Bal Sewa Yojana portal and releases standard treatment guidelines for sickle cell anemia disease
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Subscribe To Our Newsletter & Stay Updated
